Search results for "Splenectomy"

showing 10 items of 56 documents

Open Radical Nephrectomy: 35 Years of Experience at the “Luciano Giuliani” Urological Department of the University of Genoa

2006

Objective: Radical nephrectomy remains the gold standard for surgically resectable kidney neoplasms > 4 cm and, in selected cases, also in presence of metastatic disease. We reviewed the records of the patients having surgery at the University of Genoa in the last 35 yr. Methods: We have retrospectively assessed all the radical nephrectomies performed between 1970 and 2005. Among tumours of the kidney subjected to surgical treatment during this period, we found 1105 cases of histologically proven renal cell carcinoma (RCC), 965 of which had records available for the study. The number of cases per year, symptoms at diagnosis, surgical strategy, staging of the tumour, and survival were rev…

Nephrologycancer incidencemedicine.medical_treatmentkidney carcinomamorbiditysepsisRenal cell carcinomacancer diagnosiscancer mortalitynephrectomypostoperative complicationMyocardial infarctioncancer survivaldisease free survivalcancer diagnosiadrenalectomy; article; cancer diagnosis; cancer incidence; cancer mortality; cancer size; cancer staging; cancer surgery; cancer survival; disease free survival; heart infarction; human; kidney carcinoma; lung embolism; lymphadenectomy; metastasis; morbidity; nephrectomy; partial nephrectomy; postoperative complication; priority journal; sepsis; spleen injury; splenectomy; surgical technique; thrombectomyRadical nephrectomyIncidence (epidemiology)articleadrenalectomyRenal cell carcinomaNephrectomypriority journalthrombectomysepsicancer surgerylung embolismmedicine.medical_specialtypartial nephrectomyUrologyheart infarctionsurgical techniquesplenectomyInternal medicinemedicineCarcinomametastasishumanbusiness.industrycancer stagingmedicine.diseaseSurgeryspleen injurycancer sizelymphadenectomySurgerymetastasibusinessKidney cancerKidney diseaseEuropean Urology Supplements
researchProduct

Splenic marginal zone lymphoma.

2002

Splenic marginal zone lymphoma (SMZL) is a specific low-grade small B-cell lymphoma that is incorporated in the World Health Organization classification. Characteristic features are splenomegaly, moderate lymphocytosis with villous morphology, intrasinusoidal pattern of involvement of various organs, especially bone marrow, and relative indolent course. Tumor progression with increase of blastic forms and aggressive behavior are observed in a minority of patients. Molecular and cytogenetic studies have shown heterogeneous results probably because of the lack of standardized diagnostic criteria. To date, no definitive therapy has been established. Therapeutic options include treatment absten…

BendamustinePathologymedicine.medical_specialtyLymphoma B-CellLymphocytosismedicine.medical_treatmentImmunologySplenectomyBiochemistryImmunophenotypingDiagnosis DifferentialImmunophenotypingMedicineAnimalsHumansSplenic marginal zone lymphomabusiness.industryLymphoma Non-HodgkinSplenic NeoplasmsCell BiologyHematologymedicine.diseaseLymphomaTumor progressionCytogenetic AnalysisRituximabmedicine.symptombusinessmedicine.drugBlood
researchProduct

Uferzellangiom - eine seltene Differentialdiagnose von Milztumoren

2008

UNLABELLED HISTORY AND PRE-ADMISSION FINDINGS: Routine abdominal sonography of a 51-year-old man 6 years after removal of the right testis and radiotherapy for a seminoma revealed a 3 cm mass within the spleen. INVESTIGATIONS All biochemical tests were normal. Computed tomography (CT) and magnetic resonance imaging confirmed the tumour which had not been present on the CT before the seminoma had been treated. No other space-occupying lesions were found in the thorax and abdomen. TREATMENT AND COURSE A splenectomy was performed because a metachronous metastasis of the seminoma was suspected. The operation and subsequent course were uneventful. At operation the tumour had been diagnosed as an…

Thoraxmedicine.medical_specialtymedicine.diagnostic_testbusiness.industrymedicine.medical_treatmentSplenectomyMagnetic resonance imagingGeneral MedicineSeminomamedicine.diseasemedicine.anatomical_structureLittoral cell angiomamedicineRed pulpAbdomenRadiologyDifferential diagnosisbusinessDMW - Deutsche Medizinische Wochenschrift
researchProduct

Efficacy of Caplacizumab in Patients with aTTP in the HERCULES Study According to Initial Immunosuppression Regimen

2019

Background: Acquired thrombotic thrombocytopenic purpura (aTTP) is an acute, life-threatening thrombotic microangiopathy that requires urgent and specialized treatment. Prior to the introduction of caplacizumab, the treatment for aTTP was based on daily therapeutic plasma exchange (TPE; to replenish functional ADAMTS13 enzyme) plus immunosuppression (mainly corticosteroids and rituximab; to suppress anti-ADAMTS13 autoantibody production). TPE combined with immunosuppressive therapy improved outcomes in patients; however, episodes of aTTP are still associated with an acute mortality of up to 20% as these therapies do not have an immediate effect on the pathologic microvascular thrombosis. Th…

medicine.medical_specialtyCyclophosphamidebusiness.industryBortezomibmedicine.medical_treatmentImmunologySplenectomyImmunosuppressionHydroxychloroquineCell BiologyHematologyBiochemistryRegimenPharmacotherapyInternal medicinemedicineRituximabbusinessmedicine.drugBlood
researchProduct

Evans’ Syndrome: From Diagnosis to Treatment

2020

Evans’ syndrome (ES) is defined as the concomitant or sequential association of warm auto-immune haemolytic anaemia (AIHA) with immune thrombocytopenia (ITP), and less frequently autoimmune neutropenia. ES is a rare situation that represents up to 7% of AIHA and around 2% of ITP. When AIHA and ITP occurred concomitantly, the diagnosis procedure must rule out differential diagnoses such as thrombotic microangiopathies, anaemia due to bleedings complicating ITP, vitamin deficiencies, myelodysplastic syndromes, paroxysmal nocturnal haemoglobinuria, or specific conditions like HELLP when occurring during pregnancy. As for isolated auto-immune cytopenia (AIC), the determination of the primary or…

Pediatricsmedicine.medical_specialtyEvans syndromemedicine.medical_treatmentSplenectomylcsh:MedicineDiseaseReview03 medical and health sciences0302 clinical medicinehemic and lymphatic diseasesMedicineCytopeniabusiness.industryMyelodysplastic syndromeslcsh:RGeneral Medicinemedicine.diseaseEvans’ syndromeimmune thrombocytopenia030220 oncology & carcinogenesisConcomitantAutoimmune neutropeniaRituximabautoimmune haemolytic anaemiabusiness030215 immunologymedicine.drugJournal of Clinical Medicine
researchProduct

Altered distribution and function of splenic innate lymphoid cells in adult chronic immune thrombocytopenia

2018

IF 7.607; International audience; Innate lymphoid cells (ILCs) have been characterized as innate immune cells capable to modulate the immune response in the mucosae. Human ILCs have been rarely described in secondary lymphoid organs except in tonsils. Moreover, their function and phenotype in human secondary lymphoid organs during autoimmune diseases have never been studied. We took advantage of splenectomy as a treatment of immune thrombocytopenia (ITP) to describe and compare splenic ILC from 18 ITP patients to 11 controls. We first confirmed that ILC3 represented the most abundant ILC subset in human non-inflamed spleens, accounting for 90% of total ILC, and that they were mostly constit…

0301 basic medicineAdultMalemedicine.medical_treatmentImmunologySplenectomyGene ExpressionSpleenInnate lymphoid cells[SDV.CAN]Life Sciences [q-bio]/Cancer03 medical and health sciencesInterferon-gamma0302 clinical medicineImmune systemhemic and lymphatic diseasesmedicineImmunology and AllergyHumansLymphocyte CountLymphocytesskin and connective tissue diseasesAutoimmune diseasePurpura Thrombocytopenic IdiopathicInnate immune systemNatural Cytotoxicity Triggering Receptor 2business.industryMacrophagesInnate lymphoid cellInterleukin-2 Receptor alpha SubunitGranulocyte-Macrophage Colony-Stimulating FactorCell DifferentiationMiddle Agedmedicine.diseasePathophysiologyImmunity Innate3. Good healthImmune thrombocytopenia030104 developmental biologymedicine.anatomical_structureLymphatic systemCase-Control StudiesImmunologySplenectomyFemalebusinessSpleen030215 immunology
researchProduct

Splenic hemangiomas: contrast-enhanced sonographic findings

2012

Objectives The purpose of this study was to illustrate the baseline appearance and enhancement patterns of splenic hemangiomas on contrast-enhanced sonography. Methods Two experienced radiologists retrospectively reviewed by consensus baseline and contrast-enhanced sonographic examinations of 27 patients (14 women and 13 men; mean age, 58.7 years) with 27 splenic hemangiomas (mean size, 2 cm) confirmed by splenectomy, biopsy, computed tomography, and magnetic resonance imaging and follow-up. Results On baseline sonography, 77.8% of the lesions showed a homogeneous echo texture that was mainly hyperechoic. Color Doppler imaging did not show any signal in 81.5% of the cases. After contrast ag…

AdultMalemedicine.medical_specialtyContrast-enhanced sonography; spleen; splenic hemangioma; splenic neoplasmsContrast enhancementmedicine.medical_treatmentmedia_common.quotation_subjectSplenectomySulfur HexafluorideContrast MediaSensitivity and SpecificityBiopsyParenchymaMedicineContrast (vision)HumansRadiology Nuclear Medicine and imagingPhospholipidsmedia_commonAgedUltrasonographyRadiological and Ultrasound Technologymedicine.diagnostic_testbusiness.industrySplenic NeoplasmsReproducibility of ResultsMagnetic resonance imagingMiddle AgedContrast-enhanced sonographyHomogeneousspleenFemaleRadiologybusinessHemangiomaSettore MED/36 - Diagnostica Per Immagini E Radioterapiasplenic hemangiomaArterial phase
researchProduct

Sclerosing Angiomatoid Nodular Transformation: Laparoscopic Splenectomy as Therapeutic and Diagnostic Approach at the Same Time

2018

Introduction. Sclerosing angiomatoid nodular transformation (SANT) of the spleen is a rare benign vascular lesion with unknown etiopathogenesis and with definite features of imaging, histopathology, and immunohistochemistry. It was first described by Martel et al. in 2004, and to date, only 151 cases have been reported.Case Description. We report a case of SANT of the spleen detected in a 66-year-old Caucasian, without comorbidities, presented to our department with epigastric pain. We, also, presented a review of the literature.Conclusions. SANT is a benign incidentally vascular condition in the majority of cases. The wide age and gender distribution in our review is in accordance with tha…

medicine.medical_specialtybusiness.industrySclerosing angiomatoid nodular transformation spleen.medicine.medical_treatmentSplenectomylcsh:SurgeryCase ReportVascular lesionlcsh:RD1-811Case descriptionSettore MED/08 - Anatomia PatologicaLaparoscopic splenectomyEpigastric painSurgeryAge and gender03 medical and health sciencesSettore MED/18 - Chirurgia Generale0302 clinical medicine030220 oncology & carcinogenesismedicine030211 gastroenterology & hepatologyPharmacology (medical)HistopathologyRadiologybusinessCase Reports in Surgery
researchProduct

Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone as first-line treatment for splenic marginal zone ly…

2015

Rituximab ® provides high response rates and effective disease palliation in patients with splenic marginal zone lymphoma (SMZL). We conducted a phase II trial in patients with SMZL who were either untreated or were splenectomized but had shown disease progression within 1 year after splenectomy. Treatment consisted of six courses of Rituximab with cyclophosphamide, vincristine, non-pegylated liposomal doxorubicin and prednisone (R-COMP). Fifty-one patients were eligible for the analysis. The overall response rate was 84%. The 6-year progression-free survival and overall survival were 54% and 72%, respectively. Toxicity was substantial (grade ≥ 3 neutropenia: 26%; grade ≥ 3 infections: 8%).…

MaleCancer ResearchBiopsymedicine.medical_treatmentfirst lineKaplan-Meier EstimateSplenic marginal zone lymphoma; first line; rituximabPolyethylene GlycolGastroenterologyPolyethylene GlycolsrituximabBone MarrowPrednisonefirst line; rituximab; splenic marginal zone lymphomaCause of DeathAntineoplastic Combined Chemotherapy ProtocolsSplenic marginal zone lymphomaAged 80 and overHematologyMiddle AgedPrognosisCombined Modality TherapySplenic NeoplasmTreatment OutcomeItalyOncologyVincristineFemaleRituximabHumanmedicine.drugAdultmedicine.medical_specialtyVincristineLymphoma B-CellCyclophosphamidePrognosiSplenectomySplenic NeoplasmNeutropeniaImmunophenotypingfirst line; rituximab; Splenic marginal zone lymphoma; Adult; Aged; Aged 80 and over; Antineoplastic Combined Chemotherapy Protocols; Biomarkers; Biopsy; Bone Marrow; Cause of Death; Combined Modality Therapy; Cyclophosphamide; Doxorubicin; Female; Humans; Immunophenotyping; Italy; Kaplan-Meier Estimate; Lymphoma B-Cell; Male; Middle Aged; Polyethylene Glycols; Prednisone; Prognosis; Rituximab; Splenic Neoplasms; Treatment Outcome; Vincristine; Hematology; Oncology; Cancer ResearchInternal medicinemedicineHumansSplenic marginal zone lymphomaCyclophosphamideAgedAntineoplastic Combined Chemotherapy Protocolbusiness.industrySplenic NeoplasmsBiomarkermedicine.diseaseSurgeryDoxorubicinPrednisonebusinessBiomarkers
researchProduct

OC-87 Gaucher disease in romania – baseline characteristics, specific diagnosis. treatment and outcome

2017

Gaucher disease is a autosomal recessive inherited monogenic disease caused by beta-glucocerebrosidase deficiency. Clinically, there are three types: type 1 (non-neuronopathic), type 2 (acute neuronopathic) and type 3 (chronic neuronopathic), in 92%, 1% and respectively 7% of patients. Specific diagnosis has been possible in Romania since 1997 and enzyme replacement therapy since 2002. The aim of the study is to present the epidemiologic, clinical and molecular data of the Romanian patients with Gaucher disease ant their evolution. Patients and methods Seventy-nine patients (76 patients with Gaucher disease type 1 and 3 patients with Gaucher disease type 3; F/M=1.37/1) were evaluated clinic…

medicine.medical_specialtyPediatricsBone densityImigluceraseBone diseasebusiness.industryIncidence (epidemiology)medicine.medical_treatmentSplenectomyPrevalenceEnzyme replacement therapyDiseasemedicine.diseaseGastroenterologyInternal medicineMedicinebusinessmedicine.drugOral Communications
researchProduct